Co-Director, Childhood Cancer Epidemiology and Prevention Program
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
Adjunct Assistant Professor
Human Genetics Center
Division of Epidemiology,
Human Genetics and Environmental Sciences
University of Texas School of Public Health
Dr. Philip Lupo
Alkek Building for Biomedical Research, ABBR-R516
Houston, TX 77030
PhD, Epidemiology, University of Texas Health Science Center, 2009
MPH, Disease Control, University of Texas Health Science Center, 2004
BS, Biology and Political Science, Houston Baptist University, 1996
Post-doctoral fellowship, University of Texas Health Science Center, 2010
Genetic and environmental epidemiology
Member, American Association for Cancer Research
Member, American Public Health Association
Member, Brain Tumor Epidemiology Consortium
Member, Childhood Leukemia International Consortium
Member, Children’s Oncology Group
Member, Advisory Council, Focus on Rhabdo
Member, International Society for Environmental Epidemiology
Member, International Society for Pediatric Oncology
Member, Society for Epidemiologic Research
Member, Society for Pediatric and Perinatal Epidemiologic Research
Member, Advisory Committee, Texas Cancer Registry
Dr. Philip Lupo is a molecular epidemiologist in the Childhood Cancer Epidemiology and Prevention Program of the Texas Children’s Cancer Center and in the Cancer Prevention and Population Sciences Program of the Dan L. Duncan Cancer Center.
Dr. Lupo’s research focuses on the genetic and environmental determinants of adverse pediatric conditions. Genetic and environmental epidemiology, pediatric cancer, birth defects, and gene-environment interactions are among his primary research interests.
Discovering factors that can be used in childhood cancer prevention efforts and targeted interventions
Dr. Lupo is currently collaborating with other researchers and clinicians in the Texas Children’s Cancer Center to develop studies examining the role of genes and prenatal exposures on the development of childhood cancer, as well as the identification of novel risk factors for long-term complications of childhood cancer therapies.
As a member of the Children’s Oncology Group (COG) Epidemiology Committee, Dr. Lupo is working with investigators to build a research program in the epidemiology of rhabdomyosarcoma.
He is an active collaborator with the Centers for Disease Control (CDC) and Prevention-funded National Birth Defects Prevention Study (NBDPS) and is part of a multidisciplinary team of experts assessing the intersection of childhood cancer and birth defects.
The ultimate goal of Dr. Lupo’s research is to discover factors that can be used in childhood cancer prevention efforts and targeted interventions to limit the adverse consequences of childhood cancer treatment.
The metabolome and risk of pediatric acute lymphoblastic leukemia relapse
Dr. Lupo was awarded a pediatric pilot grant by Texas Children’s Hospital and Baylor College of Medicine to study the metabolome and risk of pediatric acute lymphoblastic leukemia relapse.
Innovative approaches are needed to predict and target relapsed acute lymphoblastic leukemia (ALL) in children. Despite advances in ALL treatment, approximately 20 percent of children will suffer relapsed disease. Outcomes with salvage therapy are disappointing, with only 35 percent of children surviving after disease recurrence. In fact, given the number of ALL cases each year, relapsed ALL accounts for more deaths from cancer in children than any other malignancy.
As metabolites change rapidly in response to chemotherapy, the newly emerging field of metabolomics holds great promise for predicting response to cancer therapy. Our long-term goal is to identify novel biomarkers of ALL relapse in order to improve outcomes for those with relapsed disease. The objective of this pilot project is to determine the utility of global metabolomic profiling for predicting relapse among children with ALL.
This study represents an important step toward understanding the biology of relapsed ALL and identifying biomarkers that may be useful in improved risk stratification strategies. Finally, the discovery of metabolites associated with increased risk of relapse may allow us to better target chemo-resistant disease, which ultimately may point to enhanced frontline therapies.